Should a stable patient with recent pacemaker replacement who stopped apixaban (Eliquis) and now has an acute pulmonary embolism without right‑heart strain be restarted on apixaban or started on heparin?

Restart Apixaban Immediately in This Stable PE Patient

In a hemodynamically stable patient with acute PE without right heart strain, apixaban should be restarted directly without using heparin as a bridge. This approach is supported by both FDA labeling and current guidelines for low-risk PE management.

Rationale for Direct Oral Anticoagulation

Guideline-Based Risk Stratification

This patient has low-risk PE based on:

• Hemodynamic stability
• No right heart strain on imaging
• Ability to tolerate oral medication

The 2019 ESC guidelines explicitly recommend that for intermediate- or low-risk PE, NOACs (including apixaban) are preferred over vitamin K antagonists, and when oral anticoagulation is started, parenteral bridging is not required 1. The guidelines state that LMWH or fondaparinux is recommended over UFH only "if anticoagulation is initiated parenterally" - but this is not necessary when using apixaban 1.

FDA Labeling Supports Direct Apixaban Use

The Eliquis FDA label specifically states that apixaban is NOT recommended as an alternative to unfractionated heparin only in patients with PE who present with hemodynamic instability or who may require thrombolysis or pulmonary embolectomy 2. Your patient has none of these features, making apixaban appropriate.

The AMPLIFY trial data in the FDA label demonstrates that apixaban was noninferior to enoxaparin/warfarin for preventing recurrent VTE, with significantly less bleeding 2. Importantly, apixaban can be initiated directly without parenteral overlap.

Addressing the Pacemaker Surgery Context

Timing Considerations After Device Implantation

The 2020 ACC bleeding management guideline provides clear direction: parenteral anticoagulants can often be started with close monitoring within 1 to 3 days in most patients after achieving hemostasis 3.

For patients with high thrombotic risk (which acute PE certainly represents), the guideline recommends:

• Early reinitiation once hemostasis is achieved and patient is clinically stable
• If heparin is used, unfractionated heparin is preferred only for patients at high rebleeding risk due to its short half-life and reversibility 3

Your Patient's Thrombotic Risk is Critical

The ACC guideline classifies VTE within 3 months as high thrombotic risk 3. Your patient has acute PE today - the highest possible thrombotic risk. This strongly favors immediate anticoagulation resumption.

Pacemaker Pocket Bleeding Risk is Low

Research shows that continuing oral anticoagulation during pacemaker procedures is safe 4, 5. The patient has already undergone the procedure, and if there's no active bleeding from the pocket site, the risk of rebleeding with therapeutic anticoagulation is acceptably low compared to the immediate PE risk.

Practical Implementation

Start apixaban 10 mg twice daily for 7 days, then 5 mg twice daily (standard PE dosing per FDA label 2).

Before Restarting, Verify:

• Hemostasis at pacemaker site: No active oozing, hematoma is stable or absent
• Hemodynamic stability: Confirmed by vital signs
• No contraindications: Patient can swallow, no severe renal impairment (CrCl >25 mL/min for apixaban)

When Heparin Would Be Preferred:

Use unfractionated heparin instead only if:

• Large expanding pacemaker pocket hematoma requiring intervention
• Ongoing bleeding from surgical site
• Concern for need to rapidly reverse anticoagulation in next 24-48 hours

In these scenarios, UFH allows rapid reversal with protamine if surgical re-exploration becomes necessary 3.

Common Pitfalls to Avoid

1. Don't delay anticoagulation unnecessarily: Each day without anticoagulation in acute PE increases risk of clot propagation and recurrent embolism
2. Don't use "bridging" with heparin before apixaban: This is outdated practice from the warfarin era and adds bleeding risk without benefit 1
3. Don't underdose: Use full treatment doses (10 mg BID × 7 days), not the 2.5 mg BID dose used for stroke prevention in atrial fibrillation

The most recent 2026 AHA/ACC PE guideline 6 reinforces that direct oral anticoagulants are appropriate for acute PE management in stable patients, supporting this direct-to-apixaban approach.